Sugi Predict

Sugi Predict / Compounds / SCHEMBL400097

SCHEMBL400097

SCHEMBL400097

CCOC(=O)[C@@H]1C[C@H]1C=O

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 6/20 0.38
▸ CA2 P00918 6/20 0.38
▸ CA12 O43570 5/20 0.38
▸ CA9 Q16790 5/20 0.38
▸ LMNA P02545 1/20 0.36
▸ PPM1B O75688 1/20 0.36
▸ PTPN1 P18031 1/20 0.36
▸ PPP1CC P36873 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ CAPN9 O14815 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17451842 1.00 CA1 (0.38) CA1CA2CA12CA9LMNA
SCHEMBL29132902 1.00 CA1 (0.38) CA1CA2CA12CA9LMNA
SCHEMBL208304 1.00 CA1 (0.38) CA1CA2CA12CA9LMNA
SCHEMBL17453181 1.00 CA1 (0.38) CA1CA2CA12CA9LMNA
SCHEMBL13242445 1.00 CA1 (0.38) CA1CA2CA12CA9LMNA
SCHEMBL2742456 0.86 CA1 (0.39) CA1CA2CA12CA9PPM1B
SCHEMBL12357210 0.85 PPM1B (0.39) LMNAPPM1BPTPN1PPP1CCALDH1A1
SCHEMBL2127524 0.85 PPM1B (0.39) LMNAPPM1BPTPN1PPP1CCALDH1A1
SCHEMBL1128162 0.84 CA1 (0.38) CA1CA2CA12CA9LMNA
SCHEMBL30158792 0.84 CA1 (0.38) CA1CA2CA12CA9LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739390-A1 2-(1H-INDOL-4-YL)METHYL)2H-INDAZOLE DERIVATIVES AS FACTOR B INHIBITORS Sitala Bio Ltd (GB) 2026-05-13 — — EP disclosed
US-12338219-B2 Antimalarial agents Merch Sharpe & Dohme LLC (US) 2025-06-24 — — US disclosed
EP-4061375-B1 ANTIMALARIAL AGENTS MERCK SHARP & DOHME LLC (US) 2025-06-04 — — EP disclosed
WO-2025008451-A1 2-(1H-INDOL-4-YL)METHYL)2H-INDAZOLE DERIVATIVES AS FACTOR B INHIBITORS SITALA BIO LTD (GB) 2025-01-09 — — WO disclosed
US-12024524-B2 Imidazopyridazines as modulators of IL-17 JANSSEN PHARMACEUTICA NV (BE) 2024-07-02 — — US disclosed
US-11976083-B2 Inhibitors of peptidylarginine deiminases GILEAD SCIENCES, INC. (US) 2024-05-07 — — US disclosed
CN-115551862-B Macrocyclic inhibitors of peptidyl arginine deiminase 吉利德科学公司 2024-04-12 — — CN disclosed
US-20230357254-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-11-09 — — US disclosed
US-20230192689-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2023-06-22 — — US disclosed
CN-115884810-A Imidazopyridazines as IL-17 modulators 詹森药业有限公司 2023-03-31 — — CN disclosed
US-20110092590-A1 NITRIC OXIDE DONATING PROSTAMIDES NICOX S.A. (FR) 2011-04-21 — — US disclosed
EP-2274279-A1 NITRIC OXIDE DONATING PROSTAMIDES Nicox S.A. (FR) 2011-01-19 — — EP disclosed
WO-2009136281-A1 NITRIC OXIDE DONATING PROSTAMIDES NICOX S.A. (FR) 2009-11-12 — — WO disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20070275970-A1 COMPOSITIONS FOR AFFECTING WEIGHT LOSS OREXIGEN THERAPEUTICS, INC. (US) 2007-11-29 — — US disclosed
US-20070275970-A1 COMPOSITIONS FOR AFFECTING WEIGHT LOSS OREXIGEN THERAPEUTICS, INC. (US) 2007-11-29 — — US disclosed
US-20070270357-A1 Bifunctional Macrolide Heterocyclic Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. 2007-11-22 — — US disclosed
US-20070270450-A1 COMPOSITIONS FOR AFFECTING WEIGHT LOSS OREXIGEN THERAPEUTICS, INC. (US) 2007-11-22 — — US disclosed
US-20060128765-A1 2-(Bicyclo)alkylamino-derivatives as mediators of chronic pain and inflammation MERCK & CO., INC. 2006-06-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192689-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD74, IL2, ICOS CA1 4089/4885CA2 4677/4885CA12 2566/4885
US-20060128765-A1 2-(Bicyclo)alkylamino-derivatives as mediators of chronic pain and inflammation BDKRB1, BDKRB2, LTB4R2 CA1 3387/4885CA2 2547/4885CA12 3852/4885
US-20230357254-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 IL17A, IL23R, IL15 CA1 4571/4885CA2 3989/4885CA12 4365/4885
US-12024524-B2 Imidazopyridazines as modulators of IL-17 IL17A, IL23R, IL15 CA1 4571/4885CA2 3989/4885CA12 4365/4885
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA CA1 4563/4885CA2 3206/4885CA12 4603/4885
US-20070275970-A1 COMPOSITIONS FOR AFFECTING WEIGHT LOSS MC4R, MC3R, MC5R CA1 3487/4885CA2 3269/4885CA12 3315/4885
US-11976083-B2 Inhibitors of peptidylarginine deiminases PADI4, PADI2, PADI1 CA1 2579/4885CA2 3565/4885CA12 3719/4885
US-20070270357-A1 Bifunctional Macrolide Heterocyclic Compounds and Methods of Making and Using the Same PAICS, MAP2K4, GIPR CA1 4203/4885CA2 3923/4885CA12 3663/4885
US-20110092590-A1 NITRIC OXIDE DONATING PROSTAMIDES PTGIS, PTGIR, NOS2 CA1 4248/4885CA2 1059/4885CA12 3943/4885
US-12338219-B2 Antimalarial agents CTSL, PRCP, PEPD CA1 727/4885CA2 243/4885CA12 620/4885
US-20070270450-A1 COMPOSITIONS FOR AFFECTING WEIGHT LOSS MC4R, MC3R, MC5R CA1 3487/4885CA2 3269/4885CA12 3315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.